Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations

Autor: Cyra E. Leurs, Bernard M. J. Uitdehaag, Theo Rispens, Mike P. Wattjes, Joep Killestein, Zoé L. E. van Kempen, Anke Vennegoor

Publikováno v: Multiple Sclerosis, 23(7), 995-999. SAGE Publications Ltd
MULTIPLE SCLEROSIS JOURNAL, 23(7), 995-999. SAGE Publications Ltd
Van Kempen, Z L E, Leurs, C E, Vennegoor, A, Wattjes, M P, Rispens, T, Uitdehaag, B M J & Killestein, J 2017, ' Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations ', Multiple Sclerosis, vol. 23, no. 7, pp. 995-999 . https://doi.org/10.1177/1352458516684023

Background: In recent years, a small but increasing number of neurologists choose to extend dose intervals of natalizumab with the aim of reducing the risk of progressive multifocal leukoencephalopathy (PML). This idea is based on the hypothesis that

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39e63bcfdbd31ec5a18814fec5679dcf
http://www.scopus.com/inward/record.url?scp=85020213643&partnerID=8YFLogxK

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy

Autor: D. van der Kleij, Chris H. Polman, Charlotte E. Teunissen, M.J. Wondergem, B.M.J. Uitdehaag, Mike P. Wattjes, Anke Vennegoor, B.W. van Oosten, Joep Killestein, T. Rispens

Publikováno v: Multiple Sclerosis, 21(4), 481-484. SAGE Publications Ltd
Vennegoor, A, Rispens, T, van Oosten, B W, Wattjes, M P, Wondergem, M J, Teunissen, C E, van der Kleij, D, Uitdehaag, B M J, Polman, C H & Killestein, J 2015, ' Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy ', Multiple Sclerosis, vol. 21, no. 4, pp. 481-484 . https://doi.org/10.1177/1352458514541507
Multiple sclerosis (Houndmills, Basingstoke, England), 21(4), 481-484. SAGE Publications Ltd

Progressive multifocal leukoencephalopathy (PML) is a severe complication of natalizumab treatment. Restoring immune function by plasmapheresis/immunoadsorption (PLEX/IA) is important for the outcome of PML. We report on four multiple sclerosis (MS)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::067ed7a4fe5241564c84b9ea848656fc
https://doi.org/10.1177/1352458514541507

Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

Autor: Joep Killestein, Mike P. Wattjes, Frederik Barkhof, Bob W. van Oosten, Jop P. Mostert, Anke Vennegoor

Publikováno v: Wattjes, M P, Vennegoor, A, Mostert, J, van Oosten, B W, Barkhof, F & Killestein, J 2014, ' Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? ', Journal of Neurology, vol. 261, no. 6, pp. 1139-1143 . https://doi.org/10.1007/s00415-014-7336-5
Journal of Neurology, 261(6), 1139-1143. D. Steinkopff-Verlag

The diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients in an asymptomatic stage is crucial since it is associated with better clinical outcome measures. Current diagnostic criteria on P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a046bad94adfb7f3d435d8143b7f9aad
https://doi.org/10.1007/s00415-014-7336-5

Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

Autor: Joep Killestein, Karin A van Schie, Pauline A. van Schouwenburg, Theo Rispens, Gertjan Wolbink, Anke Vennegoor, Simone Kruithof

Publikováno v: van Schie, K A, Kruithof, S, van Schouwenburg, P A, Vennegoor, A, Killestein, J, Wolbink, G & Rispens, T 2017, ' Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies : The immune response to antibody therapeutics preferentially targets the antigen-binding site ', Journal of Allergy and Clinical Immunology, vol. 139, no. 3, pp. 1035-1037.e6 . https://doi.org/10.1016/j.jaci.2016.09.014
Journal of Allergy and Clinical Immunology, 139(3), 1035-1037.e6. Mosby Inc.
Journal of allergy and clinical immunology, 139(3), 1035-1037. Mosby Inc.

This study shows that the immune response towards natalizumab, an IgG4 antibody targeting alpha4-integrins, is directed towards the antigen binding site of the drug. This extends previous observations for TNF inhibitors, suggesting that antibodies to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d63612f4249182d15035e6a3a5d96b1
https://pubmed.ncbi.nlm.nih.gov/27717666

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody

Autor: Rob C. Aalberse, Lucien A. Aarden, Joep Killestein, Astrid van Leeuwen, Anke Vennegoor, Gerrit Jan Wolbink, Theo Rispens

Publikováno v: Rispens, T, van Leeuwen, A, Vennegoor, A, Killestein, J, Aalberse, R C, Wolbink, G J & Aarden, L A 2011, ' Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody ', Analytical Biochemistry, vol. 411, no. 2, pp. 271-276 . https://doi.org/10.1016/j.ab.2011.01.001
Analytical Biochemistry, 411(2), 271-276. Academic Press Inc.
Analytical biochemistry, 411(2), 271-276. Academic Press Inc.

Human immunoglobulin G4 (IgG4) is a poor trigger of effector functions and, therefore, is the preferred subclass for therapeutic monoclonal antibodies that merely aim to block their in vivo targets. An example is natalizumab, a recombinant IgG4 antib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fef64ae3c55483a0f855f9ed3f66a2ec
https://doi.org/10.1016/j.ab.2011.01.001